Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Rush-Copley Medical Center — Aurora, Illinois
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in Illinois: - OSF Saint Anthony's Health Center — Alton, Illinois
- Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Northwestern University — Chicago, Illinois
- Rush MD Anderson Cancer Center — Chicago, Illinois
- University of Illinois — Chicago, Illinois
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Advocate Children's Hospital-Oak Lawn — Oak Lawn, Illinois
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Advocate Children's Hospital-Oak Lawn — Oak Lawn, Illinois
Phase 3 Recruiting Industry
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AM…
Sponsor: Daiichi Sankyo
NCT ID: NCT06578247
Sites in Illinois: - Robert H Lurie Comprehensive Cancer Center Northwestern University — Chicago, Illinois
- University of Illinois Hospital & Health Sciences System — Chicago, Illinois
- The University of Chicago Medical Center — Chicago, Illinois
Phase 3 Recruiting Academic/Other
A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st r…
Sponsor: PedAL BCU, LLC
NCT ID: NCT05183035
Sites in Illinois: - Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Comer Children's Hospital — Chicago, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had be…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Sites in Illinois: - University of Chicago Medical Center — Chicago, Illinois
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Illinois: - Northwestern University Hospital — Chicago, Illinois
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Sites in Illinois: - Springfield Clinic - First /ID# 270145 — Springfield, Illinois
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Saint Jude Midwest Affiliate — Peoria, Illinois
Phase 1, Phase 2 Recruiting Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04315324
Sites in Illinois: - Loyola Center for Health at Burr Ridge — Burr Ridge, Illinois
- Lurie Children's Hospital-Chicago — Chicago, Illinois
- Northwestern University — Chicago, Illinois
- University of Illinois — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Illinois: - Lurie Children's Hospital-Chicago — Chicago, Illinois
- Advocate Children's Hospital-Oak Lawn — Oak Lawn, Illinois
- Advocate Children's Hospital-Park Ridge — Park Ridge, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT04811560
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part …
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06456463
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion coho…
Sponsor: Syndax Pharmaceuticals
NCT ID: NCT04065399
Sites in Illinois: - The University of Chicago Medical Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Academic/Other
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid …
Sponsor: Beat AML, LLC
NCT ID: NCT03013998
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Industry
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), a…
Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT04996875
Sites in Illinois: - Rush University Medical Center — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Pa…
Sponsor: BIOHENG THERAPEUTICS US LLC
NCT ID: NCT07070219
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with…
Sponsor: AstraZeneca
NCT ID: NCT07155226
Sites in Illinois: - Research Site — Decatur, Illinois
Phase 1, Phase 2 Recruiting Industry
This study is testing Allo-QuadCAR01-T, a new off-the-shelf CAR-T therapy for people with hard-to-treat B-cell cancers. Unlike current CAR-T treatments that use a patient's own cells, this therapy uses donor cells that are ready to use, wh…
Sponsor: AvenCell Therapeutics, Inc.
NCT ID: NCT07284433
Sites in Illinois: - University of Chicago — Chicago, Illinois
- Northwestern University — Evanston, Illinois
Phase 1, Phase 2 Recruiting Academic/Other
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT03319901
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 2 Recruiting Network
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05289687
Sites in Illinois: - Northwestern — Chicago, Illinois
Phase 1 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring …
Sponsor: Syndax Pharmaceuticals
NCT ID: NCT06226571
Sites in Illinois: - University of Chicago — Chicago, Illinois
Phase 1 Recruiting Academic/Other
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT02074839
Sites in Illinois: - Northwestern University Medical Hospital — Chicago, Illinois
Phase 1 Recruiting Industry
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Sponsor: Carna Biosciences, Inc.
NCT ID: NCT05602363
Sites in Illinois: - Northwestern Memorial Hospital — Chicago, Illinois